(UroToday.com) Survival after orchiectomy in stage I seminoma is almost 100% and the use of CT surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, who are unlikely to die from testicular cancer, minimizing irradiation is vital. The Trial of Imaging and Surveillance in Seminoma Testis (TRISST, NCT00589537), assessed whether CTs can safely be reduced, or replaced with MRI, without an unacceptable increase in advanced relapses. At the GU ASCO 2021 annual meeting, Dr. Robert Huddart and colleagues presented results from the TRISST trial.